Stocks · News reference
Opus Genetics Says Last Patient Enrolled In Registrational Phase 3 Clinical Trial Evaluating OPGx-LCA5, Investigational Gene Therapy For LCA5-Associated Inherited Retinal Disease
Topline six-month efficacy data expected by end of 2027Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) programOpus Genetics may submit a BLA based on
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
Opus Genetics announced plans to present topline clinical data from Phase 1/2 Cohort 1 of its OPGx-BEST1 gene therapy program during an investor conference call on September 9, 2026. The company will also present full clinical datasets and additional analyses at several upcoming ophthalmology conferences including Euretina, Retina in Rio, and FLORetina.
Opus Genetics Plans To Present Topline Clinical Data From Cohort 1 Of Its Phase 1/2 Study Of OPGx-BEST1 During Investor Conference Call And Webcast On September 9
Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ETFull clinical dataset and additional analyses evaluating
RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9
RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and lowers the price target from $10 to $9.